Health Status Across Major Subgroups of Patients with Heart Failure and Preserved Ejection Fraction
European Journal of Heart Failure · 2023
DOI: 10.1002/ejhf.2831 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Heart Failure, 2023. Verfasst von Tariq Jamal Siddiqi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA. Hauptthemen laut MEDLINE: Heart Failure, Atrial Fibrillation, Diabetes Mellitus, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim, Eli Lilly and Company.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Aims
There are limited data on health status and changes in it over time across major subgroups of patients with heart failure and preserved ejection fraction (HFpEF), including ejection fraction spectrum, age, sex, region, body mass index (BMI), and comorbidities including diabetes, chronic kidney disease (CKD), anaemia, and atrial fibrillation/flutter. Methods and results In the EMPEROR-Preserved trial, the Kansas City Cardiomyopathy Questionnaire (KCCQ) was assessed at baseline, 12, 32 and 52 weeks. Determinants of baseline KCCQ score and change over time, and the impact of empagliflozin on KCCQ scores were studied in specified subgroups. A Cox model was used to assess the association between 5- and 10-point increase and 5-point decrease in KCCQ score from baseline to week 12 and later outcomes. Among 2979 participants in the placebo arm, mean KCCQ clinical summary score (CSS) was 70.7 (20.8). Older age, female sex, BMI, anaemia, and a history of diabetes, and CKD were associated with worse scores. KCCQ-CSS score improved during follow-up; patients with atrial fibrillation/flutter at enrollment (p trend = 0.014) and CKD (p trend < 0.001) had less improvement. A 5-point increase in KCCQ-CSS at week 12 was associated with lower risk of cardiovascular death or heart failure hospitalization (5%), cardiovascular death (8%), and first heart failure hospitalization (4%) subsequently. A similar trend was seen with KCCQ total symptom score (TSS) and overall summary score (OSS). Empagliflozin improved KCCQ-CSS, -TSS and -OSS scores similarly across subgroups studied except for greater improvement in patients with the highest BMI (p trend = 0.153, 0.08 and 0.078, respectively).
Conclusion
Health status in patients with HFpEF is impaired, especially in elderly, women, and those with obesity and comorbidities. Empagliflozin improved health status among all key subgroups studied with a greater effect in obese patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
- Department of Cardiology and Berlin Institute of Health Center for Regenerative Therapies, Berlin, Germany.
- German Centre for Cardiovascular Research partner site, Berlin, Germany.
- Charité Universitätsmedizin, Berlin, Germany.
- National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Chaidari, Greece.
- UnIC@RISE, Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal.
Förderung
- Boehringer Ingelheim
- Eli Lilly and Company
Zitieren
APA
Siddiqi, T. J., Anker, S. D., Filippatos, G., Ferreira, J. P., Pocock, S. J., Böhm, M., Brueckmann, M., Chopra, V. K., Iwata, T., Januzzi, J., Piña, I. L., Ponikowski, P., Senni, M., Vedin, O., Verma, S., Zhang, Y., Zannad, F., Packer, M., & Butler, J. (2023). Health Status Across Major Subgroups of Patients with Heart Failure and Preserved Ejection Fraction. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.2831
Vancouver
Siddiqi TJ, Anker SD, Filippatos G, Ferreira JP, Pocock SJ, Böhm M, et al. Health Status Across Major Subgroups of Patients with Heart Failure and Preserved Ejection Fraction. European Journal of Heart Failure. 2023. doi:10.1002/ejhf.2831
BibTeX
@article{Siddiqi2023,
author = {Siddiqi, Tariq Jamal and Anker, Stefan D and Filippatos, Gerasimos and Ferreira, João Pedro and Pocock, Stuart J and Böhm, Michael and Brueckmann, Martina and Chopra, Vijay K and Iwata, Tomoko and Januzzi, James and Piña, Ileana L and Ponikowski, Piotr and Senni, Michele and Vedin, Ola and Verma, Subodh and Zhang, Yuhui and Zannad, Faiez and Packer, Milton and Butler, Javed},
title = {Health Status Across Major Subgroups of Patients with Heart Failure and Preserved Ejection Fraction},
journal = {European Journal of Heart Failure},
year = {2023},
doi = {10.1002/ejhf.2831}
}
EUVIMED